{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:09:37Z","timestamp":1778724577260,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474134"],"award-info":[{"award-number":["82474134"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273785"],"award-info":[{"award-number":["82273785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bioorg.2026.109883","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:08:47Z","timestamp":1776294527000},"page":"109883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fragment-based discovery of pyrazole-5-carboxamide derivatives as ALK inhibitors against non-small cell lung cancer"],"prefix":"10.1016","volume":"176","author":[{"given":"Hong-Ye","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Han","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"En-Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan-Hao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109883_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113491","article-title":"Receptor tyrosine kinase-targeted cancer therapy","volume":"19","author":"Yamaoka","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109883_bb0010","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2022.13397","article-title":"EML4-ALK fusion gene in non-small cell lung cancer","volume":"24","author":"Lei","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bioorg.2026.109883_bb0015","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejmech.2018.03.071","article-title":"Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK)","volume":"151","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109883_bb0020","doi-asserted-by":"crossref","first-page":"22028","DOI":"10.18632\/oncotarget.4314","article-title":"Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer","volume":"6","author":"Karlsson","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109883_bb0025","article-title":"Differences between lung adenocarcinoma and lung squamous cell carcinoma: driver genes, therapeutic targets, and clinical efficacy","volume":"12","author":"Shen","year":"2025","journal-title":"Genes & Dis."},{"key":"10.1016\/j.bioorg.2026.109883_bb0030","doi-asserted-by":"crossref","first-page":"48625","DOI":"10.18632\/oncotarget.8015","article-title":"Evaluation and consequences of heterogeneity in the circulating tumor cell compartment","volume":"7","author":"Brouwer","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109883_bb0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"6","author":"Chia","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.bioorg.2026.109883_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0799-8","article-title":"The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer","volume":"17","author":"Cerrato","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.109883_bb0045","first-page":"499","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management, Nature reviews","volume":"19","author":"Cooper","year":"2022","journal-title":"Clinical Oncology"},{"key":"10.1016\/j.bioorg.2026.109883_bb0050","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ccr.2010.11.033","article-title":"ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time","volume":"18","author":"Gerber","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109883_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/21556660.2018.1445092","article-title":"Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis","volume":"7","author":"Dalal","year":"2018","journal-title":"J. Drug Assess."},{"key":"10.1016\/j.bioorg.2026.109883_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1451230","article-title":"Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials","volume":"14","author":"Yu","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109883_bb0065","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-014-0251-3","article-title":"Ceritinib: first global approval","volume":"74","author":"Dhillon","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109883_bb0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2217\/fon-2016-0386","article-title":"Alectinib for treatment of ALK-positive non-small-cell lung cancer","volume":"13","author":"Avrillon","year":"2017","journal-title":"Future Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.bioorg.2026.109883_bb0075","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.21037\/tlcr.2019.09.14","article-title":"New generation anaplastic lymphoma kinase inhibitors","volume":"8","author":"Delmonte","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109883_bb0080","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s40262-023-01284-w","article-title":"Clinical pharmacology of brigatinib: a next-generation anaplastic lymphoma kinase inhibitor","volume":"62","author":"Gupta","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bioorg.2026.109883_bb0085","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2147\/IJGM.S512395","article-title":"Mechanisms of resistance to ALK inhibitors and corresponding treatment strategies in lung cancer","volume":"18","author":"Xie","year":"2025","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.bioorg.2026.109883_bb0090","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109883_bb0095","article-title":"Efficacy of tyrosine kinase inhibitors in ALK and EGFR-mutated non-small cell lung cancer with brain metastases","volume":"13","author":"Shalata","year":"2025","journal-title":"Med. Sci."},{"key":"10.1016\/j.bioorg.2026.109883_bb0100","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2022-11-4","article-title":"The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks","volume":"12","author":"De Giglio","year":"2023","journal-title":"Drugs Context"},{"key":"10.1016\/j.bioorg.2026.109883_bb0105","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1021\/acs.jmedchem.6b00106","article-title":"Pyrazolylamine derivatives reveal the conformational switching between type i and type ii binding modes of anaplastic lymphoma kinase (ALK)","volume":"59","author":"Tu","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109883_bb0110","series-title":"0601 Chemical Computing Group ULC, 910\u20131010 Sherbrooke St. W.Montreal, QC H3A 2R7, 2025","author":"Molecular Operating Environment (MOE)","year":"2024"},{"key":"10.1016\/j.bioorg.2026.109883_bb0115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.apsb.2019.08.009","article-title":"Synthesis and biological evaluation of a series of 2-(((5-akly\/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.109883_bb0120","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1016\/j.bmcl.2011.05.105","article-title":"Synthesis and anti-inflammatory activity of some novel 3-phenyl-N-[3-(4-phenylpiperazin-1yl)propyl]-1H-pyrazole-5-carboxamide derivatives","volume":"21","author":"Nagarapu","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109883_bb0125","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.2174\/1871520621666210202162953","article-title":"Design, synthesis and biological evaluation of 1-methyl-1H-pyrazole-5-carboxamide derivatives as novel anti-prostate cancer agents","volume":"21","author":"Chen","year":"2021","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109883_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114311","article-title":"Discovery, optimization and evaluation of 1-(indolin-1-yl) ethan-1-ones as novel selective TRIM24\/BRPF1 bromodomain inhibitors","volume":"236","author":"Xiang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109883_bb0135","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.1021\/ic901807k","article-title":"Two-dimensional networks of lanthanide cubane-shaped dumbbells","volume":"48","author":"Savard","year":"2009","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109883_bb0140","unstructured":"The PyMOL molecular graphics system, version 2.0 Schr\u00f6dinger, LLC."},{"key":"10.1016\/j.bioorg.2026.109883_bb0145","series-title":"The PyMOL molecular graphics system","author":"Delano","year":"2002"},{"key":"10.1016\/j.bioorg.2026.109883_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.bioorg.2026.109883_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/1756-0500-5-367","article-title":"ACPYPE - antechamber python parser interface","volume":"5","author":"Sousa da Silva","year":"2012","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.bioorg.2026.109883_bb0160","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jcc.22885","article-title":"Multiwfn: a multifunctional wavefunction analyzer","volume":"33","author":"Lu","year":"2012","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.109883_bb0165","doi-asserted-by":"crossref","DOI":"10.1063\/5.0216272","article-title":"A comprehensive electron wavefunction analysis toolbox for chemists, Multiwfn","volume":"161","author":"Lu","year":"2024","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bioorg.2026.109883_bb0170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/wcms.81","article-title":"The ORCA program system","volume":"2","author":"Neese","year":"2012","journal-title":"WIREs. Comput. Mol. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:36:46Z","timestamp":1778722606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826004190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"alternative-id":["S0045206826004190"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109883","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fragment-based discovery of pyrazole-5-carboxamide derivatives as ALK inhibitors against non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109883"}}